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Abstract To ensure the early detection of recurrent disease,
all patients should undergo routine surveillance following par-
tial nephrectomy for renal cell carcinoma. In order to optimize
resource allocation and avoid unnecessary radiation exposure,
the frequency and duration of surveillance should be tailored
to the individual patient’s risk of cancer recurrence. The evi-
dence for surveillance after partial nephrectomy is presented
reviewing the current literature on prognostic models and pro-
posed surveillance protocols based on the timing and patterns
of renal cell carcinoma recurrence. In addition, we review
recent guidelines on post partial nephrectomy surveillance as
well as the literature on novel imaging techniques that may aid
in early disease discovery.
Keywords Recurrent disease . Partial nephrectomy . Renal
cell carcinoma . Radiation exposure
Introduction
The American Cancer Society estimates that approximately
60,000 new cases of renal cell carcinoma (RCC) are diag-
nosed annually in the United States [1].Worldwide, this figure
approaches 270,000 cases per year, with the highest incidence
rates in North America and Europe [2]. Over the last three
decades, there has been a steady increase in the incidence of
clinically localized RCC. This trend has been attributed to the
growing number of small renal masses incidentally detected
on cross-sectional imaging performed for non-urologic condi-
tions [3]. With this trend, treatment with partial nephrectomy
(PN) has seen widespread use [4–6] as a means to avoid the
sequelae of surgically induced chronic kidney disease associ-
ated with radical nephrectomy (RN) [7–10]. In fact, current
guidelines from the American Urological Association (AUA)
[11], National Comprehensive Cancer Network (NCCN)
[12••], and European Association of Urology (EUA) [13••]
now promote the use of PN whenever technically feasible
for the treatment of small renal tumors. With this treatment
approach, only a small minority of patients will experience a
local or distant recurrence. However, due to the aggressive
nature of metastatic RCC, longitudinal follow-up is essential
for all patients so as to ensure the early detection and timely
treatment of recurrent disease. Herein, we review the rationale
and data supporting routine surveillance following PN. Spe-
cial attention is paid to prognostic models and published sur-
veillance protocols. In addition, we highlight the follow-up
algorithms endorsed by the AUA, NCCN, and EAU.
Rationale for Oncologic Surveillance
In the current review, we maintain the presumption that with
the use of aggressive surgical management and targeted sys-
temic therapy, the early detection of recurrent RCCwill lead to
improved patient outcomes. This view is premised on the
observation that a latter detected higher metastatic burden
can limit the opportunity for surgical resection (now consid-
ered the standard therapy in cases of resectable and solitary
metastases) [14]. Moreover, in the setting of local recurrences
or metachronous tumors in the contralateral kidney, there is a
limited time period for treatment with nephron-sparing
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techniques. In addition, data from clinical trials evaluating
targeted therapy for metastatic RCC have consistently shown
worse outcomes among patients with a greater disease burden
[15, 16].
Prognosis and Surveillance
Postoperative surveillance should be tailored to the natural
history of the disease and the magnitude of risk for cancer
progression. Therefore, follow-up regimens should be based
on known independent predictors of postoperative recurrence.
This would avoid underscreening patients at high risk for pro-
gression and overscreening those at low risk. Such an ap-
proach would also result in improved resource allocation for
the health care system and a reduction in unnecessary radia-
tion exposure from diagnostic imaging [17].
Several approaches have been proposed to help predict the
risk of RCC recurrence following surgical treatment. Anatom-
ical stage has historically served as the most important prog-
nostic factor for patients with RCC. Recently, however, nu-
merous studies have demonstrated that a combination of clin-
ical and histopathological factors can better predict tumor re-
currence than that of stage alone. We present some examples
of prognostic models which can be used to establish appropri-
ate patient-tailored surveillance protocols:
Kattan et al. (MSKCC) [18] designed a nomogram to pre-
dict 5-year recurrence-free survival based on prospectively
collected data from 601 patients submitted to RN or PN.
The predictors of recurrence were symptoms at presentation
(local vs. systemic), histologic subtype (clear cell vs. papillary
vs. chromophobe), tumor size, and pT stage (AJCC 1997).
Multivariate analysis suggested no independent effect of the
type of surgery (RN vs. PN) on recurrence rate. An updated
postoperative nomogram from this same group [19] focused
on the clear cell variant only, including the following predic-
tors: size, pT stage (AJCC 2002), Fuhrman grade, necrosis,
microvascular invasion, and symptom presentation.
Leibovich and colleagues [20] from the Mayo Clinic de-
veloped an alternative algorithm to predict progression to met-
astatic RCC in patients with clinically localized clear cell RCC
after RN (at 1, 3, 5, 7, and 10 years). The features in this model
included pT and pN stage (2002 AJCC), tumor size (<10 vs.
≥10 cm), nuclear grade, and the presence of tumor necrosis.
This same group retrospectively identified 1864 patients who
underwent PN (12 %) or RN (88 %) for non-metastatic RCC
[21]. Using multivariate analysis, four scoring algorithms
were proposed to predict disease recurrence at various time
points (0.25–10 years) in specific regions of the body (abdo-
men, thorax, bone, and brain) [21]. Based on the patterns of
recurrence in the various risk groups, the authors argued that
patients with higher scores should be followed closely in the
first 2 to 3 years and require less vigorous follow-up thereafter.
Patients with moderate scores require continuous follow-up
even after the first 5 years, and patients with low scores would
require minimal to no follow-up. The retrospective nature of
this study and the variation in the follow-up protocol of the
patients included may have led to underestimation of disease
recurrence rates, prompting caution in the immediate transla-
tion of the results in a surveillance protocol. Routine screening
for brain or bone metastasis was not advocated due to their
symptomatic nature.
A third prognostic model known as The UCLA Integrated
Staging System (UISS) was developed by Ziman and co-
workers [22] and incorporates tumor node metastasis (TNM)
stage (AJCC 1997), Fuhrman Grade, and Eastern Cooperative
Oncology Group performance status to stratify patients ac-
cording to their probability of survival and tumor recurrence.
Based on the UISS staging system, a postoperative surveil-
lance protocol was created [23].
The above cited prognostic models have been externally
validated with performances ranging between 74 and 82 %
[24]. However, due to the wide variability in the timing and
pattern of treatment failure within risk groups, additional work
is needed to better risk stratify patients. One hope lies in the
development of novel biomarkers such as circulating tumor
cells and circulating tumor DNA [25, 26].
Review of Published Surveillance Protocols
By analyzing the timing and patterns of RCC recurrence, sev-
eral surveillance protocols have been proposed [23, 27–33]:
Sandock et al. [31] retrospectively reviewed 137 patients
with localized RCC, submitted to RN, and followed for
14 years. The average interval and site of RCC recurrence
were analyzed for each TNM stage (AJCC 1992). Disease
recurred in 0, 14.6, and 52.8 % of patients with pT1, pT2,
and pT3, respectively. Among patients with pT2–3, 85 % of
recurrences occurred within the first 3 years postoperatively.
The remaining 15% recurred between 3.4 and 11.4 years. The
most common sites of recurrence were the lung, liver, bone,
and brain. Notably, 73.7 % of pulmonary metastases were
symptomatic and 100 % of patients had an abnormal chest
X-ray (CXR). Regarding abdominal metastasis, 92.3 % of
patients had symptoms or abnormal serum studies. Based on
these data, the authors recommended against routine radio-
graphic follow-up of patients with pT1 RCC (defined as
≤2.5 cm by the AJCC 1992). In contrast, for patients with
pT2-3 disease, they recommended a CXR along with history
and physical exam every 6 months postoperatively for 3 years
and then yearly thereafter. In terms of imaging the abdomen,
bone, and brain, the authors recommended that computed to-
mography (CT) be performed only for a suspicion of
recurrence.
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In a similar study, Hafez et al. [28] reviewed 327 cases of
PN performed at the Cleveland Clinic and found that 38 pa-
tients (11.6 %) experienced a recurrence during a mean
follow-up of 55.6 months. Among these cases, 13 (34.3 %)
recurred locally (7 of them with metachronous metastatic dis-
ease). Recurrent RCC was detected by symptoms in 25
(65.8 %) patients and by follow-up CXR or abdominal CT
in 13 (34.3 %). Notably, no patient with pT1 RCC (defined
as ≤2.5 cm by the AJCC 1992) experienced a local recurrence
and only 3 (4.4 %) developed metastatic disease. Given these
findings, the authors recommended against radiographic sur-
veillance of patients with pT1 disease. Of patients with pT2
RCC (defined as >2.5 cm limited to the kidney by the AJCC
1992), 2% experienced a local recurrence (detected after more
than 4 years) and 5.3 % developed metastases (the lung being
the initial and most common site of metastasis). These data
revealed that although frequent early radiographic monitoring
for local tumor recurrence was likely unnecessary, abdominal
CT every 2 years was an important measure. A yearly CXR
was recommended in this group. Lastly, among patients with
pT3 RCC (invading perinephric fat/renal venous system)
treated with PN, the authors observed a local recurrence rate
of 9.3 % and metastatic recurrence rate of 13 %. Seventy
percent of the local recurrences were diagnosed within the first
2 years. The most common site of metastasis was the lung. In
light of these data, the authors recommended a biannual ab-
dominal CT in the first 2 years and every 2 years thereafter,
along with annual CXR.
In a departure from risk stratification using standard clini-
copathologic variables, Ljungberg et al. [30] recommended a
follow-up protocol based on the DNA ploidy status (diploid
vs. aneuploid) of the patient’s tumor. These authors recom-
mended against surveillance for patients with diploid pT1–
T2 tumors or with aneuploid pT1 tumors <5 cm (AJCC
1997). In contrast, the authors recommended that patients with
aneuploid pT1–T2 tumors >5 cm should be followed with
biannual CXR. Additionally, for those with pT3 tumors, ab-
dominal, CT was recommended at 6 and 12 months
postoperatively.
An innovative surveillance protocol tailored to the UISS
risk groups was presented by Lam et al. [23]. In this report, a
cohort of 559 patients surgically treated for RCC (30 % with
PN) was divided into four risk groups. Patients in the low risk
group had a recurrence rate of <10 % and a long time to
recurrence (median 28.9 months). The majority of recurrences
occurred in the lungs and one third occurred in the first year
(median 23.6 months), supporting the use of yearly chest CT
in these patients. The median time of abdominal recurrences
was 32 months and an abdominal CTwas recommended at 24
and 48 months. Surveillance after 5 years was not recom-
mended. Intermediate-risk group patients had a higher recur-
rence rate at 32%. The majority of recurrences occurred in the
chest (74.4 %) and abdomen (58.1 %), and 41.7 and 58.1 %
were diagnosed in the first year of follow-up, respectively.
Based on these data, chest CTscans were recommended every
6 months until 3 years and yearly thereafter. Abdominal CT
should be done at 1 year and every 2 years thereafter. In the
high-risk group, chest and abdominal recurrences were fre-
quent and often occurred within the first 6 months; thus, the
authors recommended serial chest CT scans every 6 months,
continuing for 3 years and yearly thereafter (after 3 years al-
ternating CXR and chest CT is acceptable). In addition, they
recommended that an abdominal CT should be done every
6 months for 2 years and yearly thereafter. Given a 7.1 and
5 % incidence of late chest and abdominal recurrences, it was
recommended that patients be followed beyond this time with
less frequent intervals. Patients with nodal disease presented
earlier and with more aggressive recurrences. Therefore, for
this group, the authors recommended that chest and abdomi-
nal CT be performed at 3, 6, 12, 18, and 24 months. A yearly
chest and abdominal CT scan would be sufficient thereafter.
The authors concluded that using this staged oriented proto-
col, patients should be followed similarly after PN or RN. A
more recent follow-up scheme was developed by Antonelli
et al. [27] based on the time and patterns of RCC recurrence
of 814 patients after RN and PN (20 %).
Siddiqui and coworkers [32] reported the first histologic
subtype specific surveillance algorithm. After reviewing
2339 patients submitted to RN or PN (15 %) at the Mayo
Clinic, a Cox proportional hazard model was used to deter-
mine which further pathological features were independently
predictive of abdominal and thoracic recurrence in each one of
three groups (clear cell, papillary, and chromophobe). For
clear cell RCC, the surveillance algorithm included the fol-
lowing features: surgical margin, pT, pN (2002 AJCC), tumor
size (<10 vs. ≥10 cm), nuclear grade, and presence of necro-
sis. For papillary and chromophobe RCC, stage and grade
were the only predictors of recurrence included in the algo-
rithm. A decrease in recurrence-free survival superior to 1 %
over a specific period (periods of 3 months during the first
3 years and yearly periods thereafter) would trigger a site-
specific imaging test. Postoperative imaging was tailored for
each histologic subtype and recurrence risk group.
Ideal Duration of Follow-up
The greatest risk of recurrence for patients with RCC exists in
the first 5 years following nephrectomy [30, 31]. In a series of
187 patients treated with RN, 43 % of metastases developed
within 1 year, 70 % within 2 years, 80 % within 3 years, and
93 % by the end of 5 years of follow-up [30]. Based on these
and similar data, it is widely held that follow-up should be
most intense during the first 3 years following surgery, with
a decrease in the frequency of surveillance in subsequent
years. It is worth noting, however, that up to 10 % of the
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patients may develop late recurrences beyond 5 years after
surgery. At the present time, however, it remains difficult to
know which patients would most benefit from imaging be-
yond 5 years of follow-up.
One study found that the development of late recurrence
was associated with lymphovascular invasion, high Fuhrman
grade (III–IV), and pathologic tumor stage >pT1 at primary
diagnosis [34]. In a related report, Adamy et al. [35] compared
patients with late recurrence to those with early recurrence
after nephrectomy. The late recurrence group patients had less
aggressive disease and were more likely to present asymptom-
atically. Of note, the lung and bones were the most frequent
late metastatic sites. However, a significant number of patients
with late recurrences were noted at unusual sites such as the
pancreas, contralateral adrenal gland, and thyroid. This obser-
vation underscores the need to maintain a high suspicion for
RCC recurrence in patients presenting history of nephrectomy
and a new lesion regardless of the affected site and the disease-
free interval
It is worth noting that positive surgical margins after PN
seem to harbor an increased risk of disease recurrence, espe-
cially in patients with tumors of high malignant potential [36].
Thus, these patients require special consideration when deter-
mining the frequency and duration of follow-up. With that
said, the vast majority of patients with a positive surgical
margin will not experience local or distant tumor recurrence.
Clearly, additional data is needed in order to determine the
optimal follow-up protocol for this patient cohort.
Surveillance Protocols Endorsed by the AUA, NCCN,
and EAU
AUA In 2013, the AUA published guidelines on the surveil-
lance of patients with clinically localized RCC [37••].
Contained within this document are specific guidelines for
patients treated with PN. For those at low risk of recurrence
(defined as pT1 RCC), the AUA recommends baseline ab-
dominal imaging with either CT or MRI at 3 to 12 months
postoperatively. For 3 years thereafter, patients may undergo
annual surveillance with CT, MRI, or ultrasound (US) of the
abdomen as well as CXR. For patients at moderate to high risk
of recurrence (defined at ≥pT2 RCC), the AUA recommends
cross-sectional imaging of the chest and abdomen at 3 to
6 months following surgery. It is further recommended that
patients undergo abdominal and chest imaging every 6months
for at least 3 years and then annually thereafter to year 5.
Follow-up imaging may be performed with a combination of
ultrasound (US), CXR, CT, and/or MRI.
NCCN The NCCN [12••] recommends baseline abdominal
imaging with CT, MRI, or US within 3 to 12 months of sur-
gery for patients with pT1 RCC. Following initial
postoperative imaging, three additional years of annual ab-
dominal and chest imaging is recommended. Chest imaging
may be performed with either CXR or CT. For the subset of
patients with ≥pT2 RCC, more rigorous follow-up is recom-
mended with chest and abdominal imaging every 3 to
6 months for 3 years and then annually for two additional
years.
EAU The 2014 guideline from the EAU [13••] proposes an
algorithm for surveillance-based risk stratification using one
of the validated classification systems (e.g., UISS). Following
a baseline US, it is recommended that patients with a low-risk
profile be imaged yearly, alternating US with chest/abdominal
CT for the next 5 years. For patients at intermediate to high
risk for recurrence, annual imaging with a chest and abdomi-
nal CT is recommended for 5 years and then biennially
thereafter.
Table 1 summarizes the guidelines from the AUA, NCCN,
and EAU. In addition, this table details the frequency of
follow-up by history, physical exam, and laboratory testing.
To date, only one report has evaluated the efficacy of the
proposed surveillance guidelines. In this study, Stewart
et al.[38] assessed the ability of the AUA 2013 and NCCN
2014 protocols to capture RCC recurrences and determined
the duration of surveillance required to capture 90, 95, and
100 % of recurrences. This retrospective analysis of 3651
patients who underwent RN or PN (27.1 %), with a median
follow-up of 9 years, revealed disease recurrence in 1088 pa-
tients. The overall recurrence detection rate, using the AUA
2013 and the NCCN 2014 protocols, were 66.9 and 68.2 %,
respectively. In the low-risk PN group (pT1N0), only 37.2 and
38.3 % of recurrences would have been captured if the AUA
2013 and NCCN 2014 schemes were followed. Better results
would be achieved with the moderate/high risk(>pT1 or pos-
itive margin) surveillance protocols with a detection rate of
about 80 %. This study revealed that to capture 95 % of re-
currences among low risk PN patients, follow-up would be
required for 15 years for the chest, 11 years for abdomen,
5 years for bone, and 11 years for other sites.
Novel Imaging Modalities
As outlined above, current guidelines support the use of CXR,
US, and cross-sectional imaging for the surveillance of pa-
tients following PN. The sensitivity of these conventional im-
aging modalities, however, are limited to target lesion sizes
>1 cm in diameter. Molecular imaging with positron emission
tomography (PET) offers superior spatial resolution and thus
the promise of earlier disease detection. At present, however,
the use of PET-based imaging remains experimental in the
setting of RCC and is not recommended in routine clinical
practice.
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The use of fluorodeoxyglucose (FDG) to functionally im-
age malignancies is based on the anticipated altered glycolytic
pathway in malignant cells (i.e., the Warburg effect). This
technique has the potential to characterize RCC at the cellular
and subcellular level in a non-invasive fashion. When used in
combination with CT, it provides functional and anatomic
tumor characteristics. Despite the unfavorable performance
of FDG-PET in diagnosing primary renal tumors, FDG-PET
may be helpful in the evaluation of recurrent RCC. In a recent
meta-analysis of the diagnostic accuracy of FDG-PET to de-
termine the presence of malignancy within the kidney and
extra renal sites, the pooled sensitivity and specificity were
79 and 90 % [39]. These results show a better accuracy to
detect extra renal RCC possibly because these lesions are
not obscured by background urinary FDG activity. It seems
that FDG-PET imaging may not localize to small lesions as
accurately as larger ones. In fact, Majhail et al. [40] showed
that the sensitivity of FDG-PET increased from 63.6 % when
considering all lesions to 92.9 % for lesions with size superior
to 2 cm. Some studies have shown that FDG-PET may local-
ize high-grade tumors more efficiently than low-grade tumors
[41].
Nakatani et al. [42] studied the value of FDG-PET to detect
recurrent and distant metastatic disease in 23 patients that had
previous nephrectomy. Overall, the sensitivity, specificity, and
diagnostic accuracy of FDG-PET for detecting recurrent ma-
lignancy were 81, 71, and 79 %, respectively. There were four
false negative results (one case of lung and brain metastasis,
one case of multiple small liver metastasis, and two cases of
metastasis to the pancreas). The findings were false positive in
two inflammatory chest lesions. This retrospective study was
affected by patient selection bias that may have overestimated
the overall accuracy. In fact FDG-PET imaging has the inher-
ent limitation of being non-cancer specific, resulting in the
accumulation of FDG in many benign tissues (infection, in-
flammation, and trauma) and normal tissues that have a phys-
iological propensity to accumulate FDG (kidneys, ureters, and
bladder).
Using antibodies that have highly selective affinity to
cancer-specific antigens, immuno-PEToffers an exciting strat-
egy to image various types of cancers, particularly RCC. The
chimeric antibody cG250 (girentuximab) binds with carbonic
anhydrase IX, a cell surface antigen highly and homogeneous-
ly expressed in more than 95 % of clear cell RCC. Divgi et al.
[43•] have shown in a multicentric phase III clinical trial
(REDECT) that 124I-girentuximab PET/CT can accurately
identify localized clear cell RCC with higher sensitivity and
specificity to contrast enhanced CT. In the setting ofmetastatic
disease, 124I-girentuximab PET has been shown to identify
anatomically occult regional node metastasis [44]. Further-
more, conventional scintigraphy showed high and specific
uptake of 111In-cG250 in metastatic lesions, including lung
lesions, considered difficult to visualize with 131I-cG250
[45]. The advantage of PET over conventional scintigraphy
is the higher spatial resolution and the ability to accurately
determine antibody uptake in tissues [46].
Conclusion
To ensure the early detection of recurrent disease, all patients
should undergo routine surveillance following PN. The fre-
quency and duration of follow-up should be tailored to the
individual patient’s risk for recurrence. Guidelines from the
AUA, NCCN, and EAU provide guidance for the surveillance
of this patient population. These recommendations, however,
are based on data from retrospective studies. Thus, additional
well-designed studies are needed to more precisely define the
optimal surveillance of patients following PN. Furthermore,
future work should aim to incorporate molecular imaging and
novel biomarkers capable of detecting early recurrences which
may otherwise be unapparent with conventional imaging
techniques.
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